P. K. Morrow

Publications84
h-index24
Citations1,747
Highly Influential Citations48
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • G. Lyman
  • 922 Publications • 57,742 Citations
  • J. Crawford
  • 396 Publications • 16,296 Citations
  • D. Dale
  • 533 Publications • 25,661 Citations
  • G. Hortobagyi
  • 1,771 Publications • 113,974 Citations
  • Publications
  • Influence
Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors.
TLDR
The KRASG12C mutation is found in approximately 13% of lung adenocarcinomas and 1–3% of other solid tumors, but there is no approved therapy that targets this mutation, and AMG 510 is a potential new drug candidate.
View via Publisher
Biosimilars 101: considerations for U.S. oncologists in clinical practice
TLDR
Broad understanding of these issues is critical for oncologists preparing for their use in clinical practice and potential cost savings should be evaluated in the context of differences in manufacturers' patient‐assistance programs, copayments, and institutional costs.
View on Wiley
Hot flashes: a review of pathophysiology and treatment modalities.
TLDR
The purpose of this paper is to assess the current options for the management of hot flashes, examining key endpoints from recent clinical trials and reviewing future directions.
View on PubMed
Neuropathic pain in breast cancer survivors: using the ID pain as a screening tool.
View on PubMed
Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy.
TLDR
Inhibition of mTOR results in clinical benefit and disease response in patients with trastuzumab-resistant HER2-overexpressing MBC, and patients with PTEN loss demonstrated decreased overall survival.
View on PubMed
Responses to liposomal Doxorubicin, bevacizumab, and temsirolimus in metaplastic carcinoma of the breast: biologic rationale and implications for stem-cell research in breast cancer.
View on PubMed
Depressive symptoms and health-related quality of life in breast cancer survivors.
TLDR
Depression is a significant health concern for breast cancer survivors and is associated with lower HRQOL and the need to monitor women with breast cancer for depression and provide resources for treating depression during the survival period is suggested.
View on PubMed
A Randomized, Double-blind, 2-Period, Placebo-Controlled Crossover Trial of a Sustained-Release Methylphenidate in the Treatment of Fatigue in Cancer Patients
TLDR
Low-dose methylphenidate did not improve cancer-related fatigue and patients takingmethylphenidate had better cognition and were able to work more hours.
View on Wolters Kluwer
Age and survival estimates in patients who have node-negative T1ab breast cancer by breast cancer subtype.
View on PubMed
Effect of age and race on quality of life in young breast cancer survivors.
View on PubMed
...
...